Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ARS Pharmaceuticals, Inc. (SPRY : NSDQ)

• Company Description    ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE. Number of Employees: 160

• Price / Volume Information    Yesterday's Closing Price: $11.65 Daily Weekly Monthly 20 Day Moving Average: 1,426,286 shares Shares Outstanding: 98.85 (millions) Market Capitalization: $1,151.59 (millions) Beta: 0.80 52 Week High: $18.90 52 Week Low: $6.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.85% 17.05% 12 Week 0.60% -1.02% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11682 El Camino Real Suite 120 - San Diego,CA 92130 USA ph: 858-771-9307 fax: - justinc@ars-pharma.com https://ars-pharma.com

• General Corporate Information    Officers Richard Lowenthal - President; Chief Executive Officer; and Director Pratik Shah - Chairman of the Board of Directors Kathleen D. Scott - Chief Financial Officer Peter Kolchinsky - Director Rajeev Dadoo - Director Peer Information ARS Pharmaceuticals, Inc. (GSAC) ARS Pharmaceuticals, Inc. (CASI) ARS Pharmaceuticals, Inc. (ALCD.) ARS Pharmaceuticals, Inc. (OMNN) ARS Pharmaceuticals, Inc. (CGPI.) ARS Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 82835W108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 98.85 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $1,151.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 7.80 Price/Cash Flow: 1,375.72 Price / Sales: 8.07 EPS Growth vs. Year Ago Period: -160.00% vs. Previous Quarter: -13.04% Sales Growth vs. Year Ago Period: 1,471.61% vs. Previous Quarter: 106.79% ROE 12/31/25 - - 09/30/25 - -38.77 06/30/25 - -21.85 ROA 12/31/25 - - 09/30/25 - -23.46 06/30/25 - -15.88 Current Ratio 12/31/25 - - 09/30/25 - 6.66 06/30/25 - 6.17 Quick Ratio 12/31/25 - - 09/30/25 - 6.51 06/30/25 - 5.98 Operating Margin 12/31/25 - - 09/30/25 - -56.06 06/30/25 - -42.74 Net Margin 12/31/25 - - 09/30/25 - -56.06 06/30/25 - -42.74 Pre-Tax Margin 12/31/25 - - 09/30/25 - -55.86 06/30/25 - -42.49 Book Value 12/31/25 - - 09/30/25 - 1.49 06/30/25 - 1.96 Inventory Turnover 12/31/25 - - 09/30/25 - 2.09 06/30/25 - 1.29 Debt-to-Equity 12/31/25 - - 09/30/25 - 1.14 06/30/25 - 0.37 Debt-to-Capital 12/31/25 - - 09/30/25 - 53.26 06/30/25 - 27.23

Powered by Zacks Investment Research ©